Reuters logo
7 months ago
BRIEF-Cellectis gets Recombinant DNA Advisory Committee's approval of UCART123 Phase 1 study protocols in AML and BPDCN
December 16, 2016 / 6:57 AM / 7 months ago

BRIEF-Cellectis gets Recombinant DNA Advisory Committee's approval of UCART123 Phase 1 study protocols in AML and BPDCN

1 Min Read

Dec 16 (Reuters) - Cellectis SA :

* Announced on Thursday Recombinant DNA Advisory Committee's (RAC) unanimous approval of UCART123 Phase 1 study protocols in AML and BPDCN

* Expects to file an Investigational New Drug (IND) application with FDA by the end of 2016

* Pending FDA clearance, plans to initiate Phase 1 clinical trials in the H1 of 2017

Source text for Eikon: Further company coverage:

Gdynia Newsroom

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below